Compare VYGR & VUZI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | VUZI |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.0M | 199.6M |
| IPO Year | 2015 | 2009 |
| Metric | VYGR | VUZI |
|---|---|---|
| Price | $3.95 | $2.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | 624.9K | ★ 843.4K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,135,000.00 | $6,280,611.00 |
| Revenue This Year | $34.04 | $103.32 |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.14 |
| 52 Week Low | $2.65 | $1.55 |
| 52 Week High | $5.55 | $4.29 |
| Indicator | VYGR | VUZI |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 55.86 |
| Support Level | $3.72 | $2.22 |
| Resistance Level | $4.30 | $2.79 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 55.45 | 97.25 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices and third-party original design manufacturer (ODM) and original equipment manufacturer (OEM) devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.